Overview
Vor Biopharma focuses on developing therapies for blood cancers, especially AML, with a platform designed to protect healthy cells while targeting cancer cells. Its product approach centers on research and development of a proprietary treatment platform and a pipeline of therapies, funded through partnerships, licensing deals, and eventual commercialization after regulatory approval. The company differentiates itself by its emphasis on selectively sparing healthy cells, a collaborative cross-functional team led by experienced biopharma leaders (including founder Dr. Siddhartha Mukherjee), and a business model built on collaborations rather than solely internal sales. The goal is to transform blood cancer treatment by delivering therapies that minimize collateral damage to healthy tissue and bring effective treatments to patients through R&D, partnerships, and eventual market commercialization.
Work here?Claim your company
About Vor Bio
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, MA
Founded
2015
Get referred to Vor Bio
See people who can refer or advise you
Simplify's take
What believers are saying
- October 22, 2026 IgAN results strengthened telitacicept's broader autoimmune franchise story.
- September 29, 2026 gMG data showed 42% achieved minimal symptom expression over 48 weeks.
- $481.6 million cash on September 30, 2026 funds operations into early 2029.
What critics are saying
- UPSTREAM MG topline in 1H27 is the binary event; failure crushes U.S. launch plans.
- Telitacicept remains unapproved outside China, so FDA and EMA review risk stays severe.
- Rising R&D burn and dependence on one asset make another program failure existential.
What makes Vor Bio unique
- Telitacicept blocks BAFF and APRIL, unlike FcRn or complement-only MG drugs.
- RemeGen's China approvals in five indications validate Vor's ex-China development thesis.
- October 22, 2026 IgAN data showed two-year kidney preservation and durable proteinuria reduction.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1B
Above
Industry Average
Funded Over
9 Rounds
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- Paid Vacation
- Parental Leave
- 401(k) Retirement Plan
- 401(k) Company Match
- Commuter Benefits
Stock Price
Growth & Insights and Company News
6 month growth
4%1 year growth
0%2 year growth
0%Vor Bio (Nasdaq: VOR) has completed enrolment in its Phase 3 UPSTREAM MG trial of telitacicept in generalised myasthenia gravis. The company expects topline results in the first half of 2027. It also plans a Phase 3 trial in ocular myasthenia gravis, with first patient dosing expected in the first half of 2027. Enrolment continues in a Phase 3 trial in primary Sjögren's disease. Vor ended the third quarter on September 30, 2026, with $481.6 million in cash and investments, which it expects to fund operations into early 2029. Research and development spending rose to $34.5 million from $14.1 million a year earlier. Net loss was $86.7 million, down from $812.7 million, mainly due to a change in the fair value of warrant liabilities.
Telitacicept shows deepening, durable response in Myasthenia Gravis. New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it. A post hoc analysis of 48-week phase 3 data found that a meaningful share of patients with generalized myasthenia gravis (gMG) treated with telitacicept reached minimal symptom expression, and that most who did sustained that level of disease control over time. Vor Bio, which is developing telitacicept outside China with partner RemeGen, presented the findings at the recently concluded in Orlando, Florida.[1] "Clinically, reaching MSE once or over a short period is not the same as sustaining that level of disease control over time,", director of the Yale Myasthenia Gravis Clinic and associate professor of neurology at Yale School of Medicine, said in a statement. Post hoc analysis of 48-week data. The analysis drew on 48-week outcomes from a phase 3 trial that randomized 114 adults with AChR or MuSK antibody-positive gMG to weekly subcutaneous telitacicept 240 mg or placebo for 24 weeks, followed by a 24-week open-label extension in which placebo recipients crossed over to telitacicept. Vor Bio defined minimal symptom expression (MSE) as an MG-ADL score of 0 or 1, and examined whether participants reached that threshold, whether they sustained it at their next monthly assessment, and what share of their remaining follow-up time was spent in MSE. Minimal symptom expression findings. About 42% of telitacicept-treated participants reached MSE at some point across the full 48 weeks, up from 23.7% within the first 24 weeks. MSE was reached by 51.2% of participants with a baseline MG-ADL score of 6 to 8, 51.7% of those with a baseline score of 9 or 10, and 20.5% of those with a baseline score of 11 or higher. Among participants who reached MSE, 86.7% of those events were sustained at the following monthly assessment. Participants initially randomized to telitacicept spent about 83% of their remaining follow-up time in MSE after first reaching it, as did about 85% of placebo recipients who crossed over to telitacicept during the open-label extension. Depth and breadth of MG-ADL improvement. More than 94% of participants achieved at least a 5-point improvement in MG-ADL by week 48, with improvements of up to 13 points observed. Responses generally deepened between weeks 24 and 48, with more participants meeting stricter improvement thresholds as treatment continued. "What stands out in these data are the breadth, depth, and durability of response," said Jean-Paul Kress, MD, chairman and chief executive officer of Vor Bio. How telitacicept works. Most MG therapies on the market or in development act downstream, decreasing circulating IgG through FcRn blockade or blocking complement activation at the neuromuscular junction; a newer anti-CD19 approach works further upstream. Telitacicept is a fusion protein combining the extracellular domain of the TACI receptor with the Fc portion of human immunoglobulin G, which Jeremy Sokolove, MD, chief medical officer of Vor Bio, described in an interview with NeurologyLive as becoming "basically a sump for BAFF and APRIL" once solubilized, neutralizing both in circulation and in tissue. Telitacicept is "pretty unique in that it does two things," Sokolove said. It reduces autoantibody-producing plasma cells and plasmablasts by withdrawing the APRIL signal they depend on for survival, while also inhibiting BAFF's effect on earlier B-cell progenitors, which Sokolove said prevents those depleted autoreactive cell populations from repopulating. "Any improvement you get, you get to keep," Sokolove said. "You don't have to go back again to lose it and to regain it." He added that B cells likely also contribute to MG independent of antibody production, noting that anti-CD19 therapies are effective in MG without substantially lowering total immunoglobulin levels. Earlier phase 3 trial and China approval. Telitacicept's MG development began in China, where RemeGen's original phase 3 trial randomized 114 adults with AChR or MuSK antibody-positive gMG, MGFA class II, III, or IVa, to weekly telitacicept 240 mg or placebo for 24 weeks. Using an analysis that imputed missing data as non-response, telitacicept reduced MG-ADL by 5.74 points from baseline compared with 0.91 points with placebo (P <.001), and reduced QMG scores by 8.66 points compared with 2.27 points with placebo (P <.001); 98.1% of telitacicept-treated participants achieved at least a 3-point MG-ADL improvement, compared with 12.0% of placebo recipients.[2] Treatment-emergent adverse events (TEAEs) occurred in 86.0% of telitacicept-treated participants and 82.5% of placebo recipients in that trial; infection-related AEs were less frequent with telitacicept (45.6%) than placebo (59.6%), and serious AEs occurred in 7.0% versus 10.5%, respectively. Based on these results, China's National Medical Products Administration for adults with AChR antibody-positive gMG used with conventional therapy, the drug's first approval in the indication.[2,3] What's next. Vor Bio and RemeGen are now running a global phase 3 trial, UPSTREAM MG (NCT06456580), designed to test whether the China results translate to a broader population. The trial is randomizing adults with AChR or MuSK antibody-positive gMG, MGFA class II through IV, with an MG-ADL score of at least 6 and a QMG score of at least 8, to weekly subcutaneous telitacicept or placebo for 24 weeks, followed by a 48-week open-label extension.[4] , and Sokolove said in the interview that Vor Bio expects a data lock roughly six months after the last patient enrolled, with topline results anticipated in the first half of 2027. "There's very little doubt that this drug should work in myasthenia gravis," he said. "The questions become how efficient we can be about the BLA process, getting this drug approved by regulators in the U.S. and globally, and then how we plan to launch it into the market." Sokolove also pointed to the open-label extension design as central to answering durability questions directly. "It's not, do I do well on a couple of days of the week," he said, "but how well do I do in the course of a chronic disease, because that's really what's important to patients."
Vor Bio to participate in upcoming September conferences. MWN-AI** Summary. Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to innovating treatments for autoimmune diseases, has announced its participation in several upcoming investor conferences throughout September 2026. The company's management aims to engage with investors and stakeholders through various formats, including fireside chats and one-on-one meetings. The schedule kicks off with the Wells Fargo 21st Annual Healthcare Conference on September 8, where Vor Bio will provide insights during a fireside chat set for 8:00 AM ET. Following that, on September 9, the company will take part in Citi's 2026 Biopharma Back to School Conference, occurring at 11:20 AM ET, again featuring a fireside chat and individual meetings. Subsequent appearances include participation in Morgan Stanley's 24th Annual Global Healthcare Conference on September 14, focused on one-on-one discussions, and the Baird 2026 Global Healthcare Conference on September 15 with a scheduled presentation at 9:05 AM ET, alongside additional meetings. Concluding this conference series, Vor Bio will present at Stifel's 2026 Virtual Immunology and Inflammation Forum on September 23 at 11:30 AM ET. Investors interested in following the discussions can access live webcasts of these presentations via the Investors section of Vor Bio's website, where replays will also be available for roughly 30 days post-event. Vor Bio is progressing its lead candidate, telitacicept - a novel dual-target fusion protein advancing through Phase 3 clinical development - aimed at addressing serious autoantibody-driven conditions globally. For further details, investors are encouraged to visit Vor Bio's website at www.vorbio.com and stay updated through the company's dedicated investor communications. MWN-AI** Analysis. Vor Bio (Nasdaq: VOR) is gearing up to participate in several prominent investor conferences this September, and this could present significant opportunities for investors to glean insights into the company's strategic direction and clinical ambitions. The market hopes to keep an eye on the presentations scheduled at conferences hosted by Wells Fargo, Citi, Morgan Stanley, Baird, and Stifel. Vor Bio is actively advancing its lead program, telitacicept, aimed at addressing critical autoimmune diseases. Robust engagement during these conferences could help elevate investor confidence, particularly as the company progresses through Phase 3 clinical trials. Investors should focus on the messaging from management during the upcoming fireside chats and presentations. Specifically, look for updates on telitacicept's clinical trial results, patient enrollment rates, and timelines toward regulatory submissions and potential commercialization. Strong clinical data announcements or proactive management during these discussions could act as price catalysts for the stock. As September is often a month filled with economic announcements and market volatility, Vor Bio's strategic participation may provide more than just clinical insights; it could serve as a bellwether for investor sentiment in the biotech sector. Given that the market tends to react positively to transparency and proactive engagement from clinical-stage companies, an effective showcasing of telitacicept's potential could foster upward momentum for VOR shares. Investors should also monitor how Vor Bio navigates questions regarding competition and market dynamics in the autoimmune treatment landscape. These insights are vital as they may address investor concerns around differentiation and market positioning. In summary, the upcoming conferences are a crucial juncture for Vor Bio, representing an opportunity for strong engagement with the investment community. Cautious investors may consider positioning themselves ahead of these events while keeping a close watch on developments. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 01, 2026 08:00:00 am BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: * Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET * Citi's 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET * Morgan Stanley 24th Annual Global Healthcare Conference Forum: 1x1 Meetings Date: Monday, September 14th * Baird's 2026 Global Healthcare Conference Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET * Stifel's 2026 Virtual Immunology and Inflammation Forum Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation. About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the "Investors" section of its website. The Company encourages investors to consult that section of its website regularly. Media & Investor Contacts:Carl [email protected] FAQ**. How does Vor Biopharma Inc. VOR plan to differentiate its dual-target fusion protein, telitacicept, from existing treatments for autoimmune diseases presented at the upcoming investor conferences? Vor Biopharma Inc. plans to differentiate telitacicept by showcasing its dual-target mechanism that potentially offers enhanced efficacy and safety over existing treatments for autoimmune diseases during the upcoming investor conferences. What specific data or progress regarding telitacicept will Vor Biopharma Inc. VOR share during the Wells Fargo and Citi conferences that could impact investor sentiment? Vor Biopharma Inc. is expected to share updated clinical trial results and potential partnerships for telitacicept during the Wells Fargo and Citi conferences, which could significantly impact investor sentiment towards the drug's efficacy and market potential. Can you elaborate on Vor Biopharma Inc. VOR's timeline for Phase 3 clinical development and what milestones will be highlighted during the investor presentations? As of now, Vor Biopharma Inc. is expected to provide updates on its Phase 3 clinical development timeline and key milestones at upcoming investor presentations, focusing on the advancements of its lead candidate and the anticipated enrollment of patients in 2026. How does Vor Biopharma Inc. VOR intend to leverage feedback from investors at the upcoming conferences to shape its commercialization strategies for telitacicept? Vor Biopharma Inc. plans to gather investor insights at upcoming conferences to refine its commercialization strategies for telitacicept, focusing on market needs and feedback to enhance product positioning and stakeholder engagement. **MWN-AI FAQ is based on asking OpenAI questions about Vor Biopharma Inc. (NASDAQ: VOR).
Vor Bio reported second quarter 2026 financial results and provided updates on its clinical programmes for telitacicept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The company reported a cash position of $466.1 million as of 30 June 2026. Combined with $48.4 million in net proceeds from July 2026 at-the-market sales, the pro-forma balance of $514.5 million is projected to fund operations into early 2029. Enrollment continues for the Phase 3 UPSTREAM MG trial in generalised myasthenia gravis, with topline results anticipated in the first half of 2027. Enrollment is also ongoing for the Phase 3 UPSTREAM SjD trial in primary Sjögren's disease. Telitacicept has received commercial approvals in China for treating Sjögren's disease and IgA nephropathy, bringing its total to five approved indications in the country.
Vor Bio appoints David Zaccardelli to Board of Directors. July 7, 2026 BOSTON, July 07, 2026 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory approval, and commercial launch. "We are excited to welcome David to the Board of Directors at an important stage in the company's evolution," said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. "David is a proven biotech operator with a distinguished track record of leading companies through periods of significant growth, from late-stage development to commercial execution. His experience building organizations, launching medicines, and creating shareholder value will be invaluable as we advance telitacicept through global Phase 3 development and build a leading immunology company." Dr. Zaccardelli served as President, Chief Executive Officer, and on the board of directors of Verona Pharma from February 2020 until its acquisition by Merck for $10 billion in October 2025. During his tenure, Verona advanced from a clinical-stage company to a commercial-stage organization, successfully completing two Phase 3 trials, receiving FDA approval, and launching Ohtuvayre(R) for chronic obstructive pulmonary disease. Under his leadership, Verona raised more than $1 billion to support development and commercialization and became one of the top-performing biotechnology companies on Nasdaq in 2024 based on its five-year increase in market value. Dr. Zaccardelli was recognized as Executive of the Year at the 2023 Scrip Awards. Currently, he serves as Chair of the Board of Directors for SAB BIO and Founder and Managing Member of Bull City Select Investments, LLC. Prior to Verona, Dr. Zaccardelli served as President and Chief Executive Officer of Dova Pharmaceuticals, a rare disease company acquired by Swedish Orphan Biovitrum in 2019 for up to $915 million. He previously served as Acting Chief Executive Officer of Cempra through its merger with Melinta Therapeutics and held several senior leadership roles at United Therapeutics Corporation, including Chief Operating Officer, Chief Manufacturing Officer and Executive Vice President, Pharmaceutical Development and Operations. Earlier in his career, Dr. Zaccardelli founded and led a contract research start-up and held clinical research roles at Burroughs Wellcome, Glaxo Wellcome and Bausch & Lomb Pharmaceutical. He received a Pharm.D. from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina. "Vor is at an exciting inflection point," said Dr. Zaccardelli. "Telitacicept has the potential to become an important therapy across multiple autoimmune diseases, and Vor has the team, capital and urgency to execute. I look forward to working with Jean-Paul, the Board, and the management team as the company advances telitacicept and enters its next phase of growth." In connection with Dr. Zaccardelli's appointment, Andrew Levin, M.D., Ph.D., an Advisor at RA Capital Management, has stepped down from Vor Bio's Board of Directors. "On behalf of the Board and management team, I want to thank Andrew for his leadership, counsel and commitment to Vor," said Dr. Kress. "Andrew has been an instrumental partner during a pivotal period of transformation for the company and we are grateful for his many contributions." About Telitacicept Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren's disease (SjD). Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan. About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the "Investors" section of its website. The Company encourages investors to consult that section of its website regularly. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "continue," "could," "design," "expect," "intend," "may," "ongoing," "plan," "potential," "should," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding telitacicept's potential to become an important therapy across multiple autoimmune diseases; Vor Bio's development and commercialization plans for telitacicept; Vor Bio's board of directors' transition; and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including that the data for its product candidates may not be sufficient for obtaining regulatory approval to commercialize products; Vor Bio, Inc. may not be able to execute its business plans, including meeting its planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Media & Investor Contacts: Carl Mauch [email protected]
There are no jobs for Vor Bio right now.
Find jobs on Simplify and start your career today
We update Vor Bio's jobs every few hours, so check again soon!Browse all jobs
About Vor Bio
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
Boston, MA
Founded
2015
There are no jobs for Vor Bio right now.
Find jobs on Simplify and start your career today
We update Vor Bio's jobs every few hours, so check again soon!Browse all jobs